Dáil Éireann Debate, Thursday - 1 June 2023
373. Deputy Róisín Shortall asked the Minister for Health the status of a review (details supplied) which examined the governance arrangements around the HSEs drug pricing and reimbursement process; if the implementation group has been established; the timeline this group is working towards to progress the implementation of the recommendations; and if he will make a statement on the matter. [27026/23]
View answerIn February, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. I fully support the recommendations contained in the Mazars report around improving the process, increasing transparency, providing easier access, and supporting value for money.
An implementation group has been established between my Department and the HSE to consider and progress the various recommendations contained in the Report. The Group has met on a number of occasions and is currently embarking on a targeted stakeholder engagement process including patient groups and industry, in seeking to bring about further improvements to the reimbursement process.
The membership of the Group includes representatives of the Drugs Group, the HSE, the NCPE, and the Department of Health.
The working group will report on their progress in the autumn.
